The GTPase NRas pipeline drugs market research report outlays comprehensive information on the GTPase NRas targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the GTPase NRas pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Melanoma. It also reviews key players involved in GTPase NRas targeted therapeutics development with respective active and dormant or discontinued products.
The GTPase NRas pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 4, and 4 respectively.
GTPase NRas overview
GTPase NRas is a member of the Ras family of GTPases, which are small proteins that play a crucial role in cellular signal transduction. NRas, like other Ras proteins, consists of a catalytic domain and a C-terminal membrane-anchoring region. The catalytic domain is involved in nucleotide binding and hydrolysis, and it undergoes conformational changes during the activation cycle.
For a complete picture of GTPase NRas’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.